Virginia Meca‐Lallana
YOU?
Author Swipe
View article: Recommendations for the critical reading of clinical trials on disease-modifying drugs for multiple sclerosis
Recommendations for the critical reading of clinical trials on disease-modifying drugs for multiple sclerosis Open
This study proposes consensus recommendations intended to guide neurologists in the critical reading of phase III and IV clinical trials on DMDs for MS.
View article: How do neurologists perceive the organization and functioning of multiple sclerosis care units?
How do neurologists perceive the organization and functioning of multiple sclerosis care units? Open
This study assessed how neurologists perceive the organization and functioning of multiple sclerosis care units. As a cross-sectional, observational study conducted in collaboration with the Spanish Society of Neurology, an electronic surv…
View article: Neurologists’ Openness to Evidence-Based Innovation in Multiple Sclerosis Care: Individual and Structural Determinants
Neurologists’ Openness to Evidence-Based Innovation in Multiple Sclerosis Care: Individual and Structural Determinants Open
Neurologists exhibited a varied openness to innovation. Implementing initial innovative strategies in clinical practice should prioritize neurologists with specific profiles to support the integration of emerging tools and personalized hea…
View article: Inflammatory bowel disease and multiple sclerosis
Inflammatory bowel disease and multiple sclerosis Open
Introduction: Inflammatory bowel disease (IBD), which mainly includes Crohn’s disease and ulcerative colitis, is characterised by chronic inflammation in the gastrointestinal tract, triggered and perpetuated by an altered immune response. …
View article: Economic burden of secondary progressive multiple sclerosis: DISCOVER study
Economic burden of secondary progressive multiple sclerosis: DISCOVER study Open
The trial is a non-interventional study. The NCC code is CBAF312AES01/NOV-EMS-2019-01.
View article: Attitudes of Neurologists Toward Serum Neurofilament Light-Chain Testing in the Management of Relapsing–Remitting Multiple Sclerosis with Cognitive Impairment
Attitudes of Neurologists Toward Serum Neurofilament Light-Chain Testing in the Management of Relapsing–Remitting Multiple Sclerosis with Cognitive Impairment Open
Background: Cognitive impairment has an impact upon the function and quality of life of patients with multiple sclerosis (MS). High-serum neurofilament light-chain (sNfL) levels predict disease progression and are also associated with impa…
View article: Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis Open
[This corrects the article DOI: 10.3389/fimmu.2024.1480676.].
View article: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis Open
Objective To ascertain the changes of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) values in relapsing–remitting multiple sclerosis (RRMS) patients treated with ocrelizumab and their association with t…
View article: Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study
Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study Open
This study shows that alemtuzumab reduced the relapse rate and disability worsening in real-world clinical practice, with many patients achieving and sustaining NEDA-3 over time. The safety profile of alemtuzumab was consistent with previo…
View article: Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management
Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management Open
Recent advances in multiple sclerosis (MS) management have shifted perspectives on treatment strategies, advocating for the early initiation of high-efficacy disease-modifying therapies (heDMTs). This perspective review discusses the ratio…
View article: Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain
Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain Open
Besides the potential benefits of convenient administration and improving work-life balance, as suggested by the expert panel, natalizumab SC was associated with cost savings for the healthcare system by avoiding drug preparation, reducing…
View article: Disability and Fatigue in Multiple Sclerosis: Can Rehabilitation Improve Them through a Structured Retraining Program?
Disability and Fatigue in Multiple Sclerosis: Can Rehabilitation Improve Them through a Structured Retraining Program? Open
Functional rehabilitation programs in multiple sclerosis have demonstrated their efficacy in improving fatigue. The assessment of functional impairment, however, is more difficult. The purpose is to assess fatigue and disability as a first…
View article: Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder
Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder Open
Background: The frequency of cognitive impairment (CI) reported in neuromyelitis optica spectrum disorder (NMOSD) is highly variable, and its relationship with demographic and clinical characteristics is poorly understood. We aimed to desc…
View article: Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology
Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology Open
Objective To ascertain the role of inflammation in the response to ocrelizumab in primary-progressive multiple sclerosis (PPMS). Methods Multicenter prospective study including 69 patients with PPMS who initiated ocrelizumab treatment, cla…
View article: Information-Seeking Strategies of People with Multiple Sclerosis in Spain: The INFOSEEK-MS Study
Information-Seeking Strategies of People with Multiple Sclerosis in Spain: The INFOSEEK-MS Study Open
Yolanda Higueras,1 Elisa Salas,2 Virginia Meca-Lallana,3 Pedro Carrascal Rueda,4 Ofir Rodríguez De la Fuente,5 Rosana Cabello-Moruno,2 Jorge Maurino,2 Miguel Ángel Ruiz Díaz6 1Department of Neurology, Instituto de Investigación Sanitaria G…
View article: Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry
Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry Open
Objective To describe the profile of patients with multiple sclerosis (MS) treated with fingolimod in Spain and to assess the effectiveness and safety of fingolimod after 4 years of inclusion in the Spanish Gilenya Registry. Methods An obs…
View article: Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses Open
Background: Plasma concentration of natalizumab falls above the therapeutic threshold in many patients who, therefore, receive more natalizumab than necessary and have higher risk of progressive multifocal leukoencephalopathy. Objective: T…
View article: Quantifying the patient´s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire
Quantifying the patient´s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire Open
Background The assessment of self-reported outcomes in neuromyelitis optica spectrum disorder (NMOSD) is limited by the lack of validated disease-specific measures. The SymptoMScreen (SyMS) is a patient-reported questionnaire for measuring…
View article: SARS-CoV-2 Infection in Multiple Sclerosis
SARS-CoV-2 Infection in Multiple Sclerosis Open
This study has not demonstrated the presumed critical role of MS therapy in the course of COVID-19 but evidenced that people with MS with advanced age and disease, in progressive course, and those who are more disabled have a higher probab…
View article: Risk and outcomes of COVID‐19 in patients with multiple sclerosis
Risk and outcomes of COVID‐19 in patients with multiple sclerosis Open
Background and purpose Limited information is available on incidence and outcomes of COVID‐19 in patients with multiple sclerosis (MS). This study investigated the risks of SARS‐CoV‐2 infection and COVID‐19‐related outcomes in patients wit…
View article: Deciphering Multiple Sclerosis Progression
Deciphering Multiple Sclerosis Progression Open
Multiple sclerosis (MS) is primarily an inflammatory and degenerative disease of the central nervous system, triggered by unknown environmental factors in patients with predisposing genetic risk profiles. The prevention of neurological dis…